nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—VEGFA—hematologic cancer	0.302	0.788	CbGaD
Gliclazide—ALB—hematologic cancer	0.0811	0.212	CbGaD
Gliclazide—CYP2C9—Bexarotene—hematologic cancer	0.0257	0.0903	CbGbCtD
Gliclazide—ALB—Imatinib—hematologic cancer	0.0214	0.0752	CbGbCtD
Gliclazide—CYP2C9—Idarubicin—hematologic cancer	0.0213	0.0748	CbGbCtD
Gliclazide—CYP2C19—Bortezomib—hematologic cancer	0.0189	0.0665	CbGbCtD
Gliclazide—CYP2C19—Thalidomide—hematologic cancer	0.0165	0.058	CbGbCtD
Gliclazide—CYP2C9—Bortezomib—hematologic cancer	0.0157	0.0553	CbGbCtD
Gliclazide—CYP2C19—Teniposide—hematologic cancer	0.0157	0.0553	CbGbCtD
Gliclazide—CYP2C19—Ifosfamide—hematologic cancer	0.0145	0.051	CbGbCtD
Gliclazide—ALB—Prednisone—hematologic cancer	0.0141	0.0495	CbGbCtD
Gliclazide—CYP2C19—Imatinib—hematologic cancer	0.0139	0.0487	CbGbCtD
Gliclazide—CYP2C9—Thalidomide—hematologic cancer	0.0137	0.0482	CbGbCtD
Gliclazide—ALB—Irinotecan—hematologic cancer	0.0134	0.047	CbGbCtD
Gliclazide—CYP2C9—Teniposide—hematologic cancer	0.0131	0.046	CbGbCtD
Gliclazide—CYP2C9—Ifosfamide—hematologic cancer	0.0121	0.0424	CbGbCtD
Gliclazide—CYP2C9—Imatinib—hematologic cancer	0.0115	0.0405	CbGbCtD
Gliclazide—CYP2C9—Nilotinib—hematologic cancer	0.0105	0.0368	CbGbCtD
Gliclazide—CYP2C19—Prednisone—hematologic cancer	0.00914	0.0321	CbGbCtD
Gliclazide—ALB—Methotrexate—hematologic cancer	0.00707	0.0249	CbGbCtD
Gliclazide—CYP2C9—Cisplatin—hematologic cancer	0.00587	0.0206	CbGbCtD
Gliclazide—CYP2C19—Dexamethasone—hematologic cancer	0.00571	0.0201	CbGbCtD
Gliclazide—CYP2C9—Dexamethasone—hematologic cancer	0.00474	0.0167	CbGbCtD
Gliclazide—KCNJ11—hematopoietic system—hematologic cancer	0.000535	0.14	CbGeAlD
Gliclazide—VEGFA—bone marrow—hematologic cancer	0.000479	0.126	CbGeAlD
Gliclazide—VEGFA—lung—hematologic cancer	0.000434	0.114	CbGeAlD
Gliclazide—VEGFA—testis—hematologic cancer	0.00041	0.108	CbGeAlD
Gliclazide—Glyburide—ABCC3—hematologic cancer	0.000322	0.455	CrCbGaD
Gliclazide—VEGFA—lymph node—hematologic cancer	0.000297	0.078	CbGeAlD
Gliclazide—CYP2C19—hematopoietic system—hematologic cancer	0.000284	0.0746	CbGeAlD
Gliclazide—ABCC8—testis—hematologic cancer	0.00027	0.0709	CbGeAlD
Gliclazide—CYP2C9—hematopoietic system—hematologic cancer	0.00022	0.0578	CbGeAlD
Gliclazide—KCNJ11—lymph node—hematologic cancer	0.000212	0.0558	CbGeAlD
Gliclazide—VEGFA—Dexamethasone—Betamethasone—hematologic cancer	0.000209	0.131	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Dexamethasone—hematologic cancer	0.000209	0.131	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Triamcinolone—hematologic cancer	0.000204	0.128	CbGdCrCtD
Gliclazide—VEGFA—Dexamethasone—Triamcinolone—hematologic cancer	0.000204	0.128	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Prednisone—hematologic cancer	0.000194	0.122	CbGdCrCtD
Gliclazide—VEGFA—Dexamethasone—Prednisone—hematologic cancer	0.000194	0.122	CbGdCrCtD
Gliclazide—ALB—testis—hematologic cancer	0.000193	0.0508	CbGeAlD
Gliclazide—VEGFA—Dexamethasone—Prednisolone—hematologic cancer	0.000189	0.119	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Prednisolone—hematologic cancer	0.000189	0.119	CbGdCrCtD
Gliclazide—CYP2C19—blood—hematologic cancer	0.000188	0.0494	CbGeAlD
Gliclazide—Glyburide—ABCG2—hematologic cancer	0.000156	0.221	CrCbGaD
Gliclazide—CYP2C9—blood—hematologic cancer	0.000146	0.0383	CbGeAlD
Gliclazide—ALB—lymph node—hematologic cancer	0.00014	0.0368	CbGeAlD
Gliclazide—Chlorpropamide—ABCB1—hematologic cancer	9.63e-05	0.136	CrCbGaD
Gliclazide—Glyburide—ALB—hematologic cancer	6.82e-05	0.0964	CrCbGaD
Gliclazide—Glyburide—ABCB1—hematologic cancer	6.51e-05	0.092	CrCbGaD
Gliclazide—Back pain—Methotrexate—hematologic cancer	1.66e-05	7.53e-05	CcSEcCtD
Gliclazide—Fatigue—Dexamethasone—hematologic cancer	1.66e-05	7.53e-05	CcSEcCtD
Gliclazide—Fatigue—Betamethasone—hematologic cancer	1.66e-05	7.53e-05	CcSEcCtD
Gliclazide—Chills—Epirubicin—hematologic cancer	1.66e-05	7.51e-05	CcSEcCtD
Gliclazide—Pruritus—Etoposide—hematologic cancer	1.66e-05	7.5e-05	CcSEcCtD
Gliclazide—Arrhythmia—Epirubicin—hematologic cancer	1.65e-05	7.48e-05	CcSEcCtD
Gliclazide—Pain—Betamethasone—hematologic cancer	1.65e-05	7.46e-05	CcSEcCtD
Gliclazide—Pain—Dexamethasone—hematologic cancer	1.65e-05	7.46e-05	CcSEcCtD
Gliclazide—Visual impairment—Doxorubicin—hematologic cancer	1.65e-05	7.46e-05	CcSEcCtD
Gliclazide—Nervous system disorder—Prednisone—hematologic cancer	1.64e-05	7.46e-05	CcSEcCtD
Gliclazide—Tachycardia—Prednisone—hematologic cancer	1.64e-05	7.42e-05	CcSEcCtD
Gliclazide—Skin disorder—Prednisone—hematologic cancer	1.63e-05	7.38e-05	CcSEcCtD
Gliclazide—Nausea—Gemcitabine—hematologic cancer	1.63e-05	7.38e-05	CcSEcCtD
Gliclazide—Vomiting—Cisplatin—hematologic cancer	1.62e-05	7.36e-05	CcSEcCtD
Gliclazide—Hyperhidrosis—Prednisone—hematologic cancer	1.62e-05	7.35e-05	CcSEcCtD
Gliclazide—Mental disorder—Epirubicin—hematologic cancer	1.62e-05	7.33e-05	CcSEcCtD
Gliclazide—Erythema multiforme—Doxorubicin—hematologic cancer	1.61e-05	7.32e-05	CcSEcCtD
Gliclazide—Rash—Cisplatin—hematologic cancer	1.61e-05	7.3e-05	CcSEcCtD
Gliclazide—Dermatitis—Cisplatin—hematologic cancer	1.61e-05	7.29e-05	CcSEcCtD
Gliclazide—Malnutrition—Epirubicin—hematologic cancer	1.61e-05	7.29e-05	CcSEcCtD
Gliclazide—Erythema—Epirubicin—hematologic cancer	1.61e-05	7.29e-05	CcSEcCtD
Gliclazide—Diarrhoea—Etoposide—hematologic cancer	1.6e-05	7.26e-05	CcSEcCtD
Gliclazide—Eye disorder—Doxorubicin—hematologic cancer	1.6e-05	7.24e-05	CcSEcCtD
Gliclazide—Ill-defined disorder—Methotrexate—hematologic cancer	1.59e-05	7.22e-05	CcSEcCtD
Gliclazide—Tinnitus—Doxorubicin—hematologic cancer	1.59e-05	7.22e-05	CcSEcCtD
Gliclazide—Anaemia—Methotrexate—hematologic cancer	1.59e-05	7.2e-05	CcSEcCtD
Gliclazide—Feeling abnormal—Dexamethasone—hematologic cancer	1.59e-05	7.19e-05	CcSEcCtD
Gliclazide—Feeling abnormal—Betamethasone—hematologic cancer	1.59e-05	7.19e-05	CcSEcCtD
Gliclazide—Flushing—Doxorubicin—hematologic cancer	1.58e-05	7.19e-05	CcSEcCtD
Gliclazide—Flatulence—Epirubicin—hematologic cancer	1.58e-05	7.18e-05	CcSEcCtD
Gliclazide—Tension—Epirubicin—hematologic cancer	1.58e-05	7.15e-05	CcSEcCtD
Gliclazide—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.57e-05	7.14e-05	CcSEcCtD
Gliclazide—Gastrointestinal pain—Betamethasone—hematologic cancer	1.57e-05	7.14e-05	CcSEcCtD
Gliclazide—Hypersensitivity—Triamcinolone—hematologic cancer	1.56e-05	7.09e-05	CcSEcCtD
Gliclazide—Nervousness—Epirubicin—hematologic cancer	1.56e-05	7.08e-05	CcSEcCtD
Gliclazide—Back pain—Epirubicin—hematologic cancer	1.55e-05	7.05e-05	CcSEcCtD
Gliclazide—Malaise—Methotrexate—hematologic cancer	1.55e-05	7.02e-05	CcSEcCtD
Gliclazide—Dizziness—Etoposide—hematologic cancer	1.55e-05	7.01e-05	CcSEcCtD
Gliclazide—Leukopenia—Methotrexate—hematologic cancer	1.54e-05	6.97e-05	CcSEcCtD
Gliclazide—Chills—Doxorubicin—hematologic cancer	1.53e-05	6.95e-05	CcSEcCtD
Gliclazide—Urticaria—Dexamethasone—hematologic cancer	1.53e-05	6.93e-05	CcSEcCtD
Gliclazide—Urticaria—Betamethasone—hematologic cancer	1.53e-05	6.93e-05	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.53e-05	6.93e-05	CcSEcCtD
Gliclazide—Dizziness—Prednisolone—hematologic cancer	1.53e-05	6.92e-05	CcSEcCtD
Gliclazide—Arrhythmia—Doxorubicin—hematologic cancer	1.53e-05	6.92e-05	CcSEcCtD
Gliclazide—Asthenia—Triamcinolone—hematologic cancer	1.52e-05	6.9e-05	CcSEcCtD
Gliclazide—Body temperature increased—Betamethasone—hematologic cancer	1.52e-05	6.9e-05	CcSEcCtD
Gliclazide—Abdominal pain—Dexamethasone—hematologic cancer	1.52e-05	6.9e-05	CcSEcCtD
Gliclazide—Body temperature increased—Dexamethasone—hematologic cancer	1.52e-05	6.9e-05	CcSEcCtD
Gliclazide—Abdominal pain—Betamethasone—hematologic cancer	1.52e-05	6.9e-05	CcSEcCtD
Gliclazide—Nausea—Cisplatin—hematologic cancer	1.52e-05	6.88e-05	CcSEcCtD
Gliclazide—Insomnia—Prednisone—hematologic cancer	1.52e-05	6.88e-05	CcSEcCtD
Gliclazide—Paraesthesia—Prednisone—hematologic cancer	1.51e-05	6.83e-05	CcSEcCtD
Gliclazide—Pruritus—Triamcinolone—hematologic cancer	1.5e-05	6.81e-05	CcSEcCtD
Gliclazide—Cough—Methotrexate—hematologic cancer	1.5e-05	6.79e-05	CcSEcCtD
Gliclazide—Mental disorder—Doxorubicin—hematologic cancer	1.5e-05	6.78e-05	CcSEcCtD
Gliclazide—Ill-defined disorder—Epirubicin—hematologic cancer	1.49e-05	6.76e-05	CcSEcCtD
Gliclazide—Convulsion—Methotrexate—hematologic cancer	1.49e-05	6.74e-05	CcSEcCtD
Gliclazide—Vomiting—Etoposide—hematologic cancer	1.49e-05	6.74e-05	CcSEcCtD
Gliclazide—Erythema—Doxorubicin—hematologic cancer	1.49e-05	6.74e-05	CcSEcCtD
Gliclazide—Malnutrition—Doxorubicin—hematologic cancer	1.49e-05	6.74e-05	CcSEcCtD
Gliclazide—Anaemia—Epirubicin—hematologic cancer	1.49e-05	6.73e-05	CcSEcCtD
Gliclazide—Agitation—Epirubicin—hematologic cancer	1.48e-05	6.69e-05	CcSEcCtD
Gliclazide—Dyspepsia—Prednisone—hematologic cancer	1.48e-05	6.69e-05	CcSEcCtD
Gliclazide—Rash—Etoposide—hematologic cancer	1.47e-05	6.69e-05	CcSEcCtD
Gliclazide—Dermatitis—Etoposide—hematologic cancer	1.47e-05	6.68e-05	CcSEcCtD
Gliclazide—Headache—Etoposide—hematologic cancer	1.47e-05	6.64e-05	CcSEcCtD
Gliclazide—Flatulence—Doxorubicin—hematologic cancer	1.46e-05	6.64e-05	CcSEcCtD
Gliclazide—Arthralgia—Methotrexate—hematologic cancer	1.46e-05	6.63e-05	CcSEcCtD
Gliclazide—Chest pain—Methotrexate—hematologic cancer	1.46e-05	6.63e-05	CcSEcCtD
Gliclazide—Myalgia—Methotrexate—hematologic cancer	1.46e-05	6.63e-05	CcSEcCtD
Gliclazide—Tension—Doxorubicin—hematologic cancer	1.46e-05	6.61e-05	CcSEcCtD
Gliclazide—Rash—Prednisolone—hematologic cancer	1.45e-05	6.6e-05	CcSEcCtD
Gliclazide—Dermatitis—Prednisolone—hematologic cancer	1.45e-05	6.59e-05	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.45e-05	6.58e-05	CcSEcCtD
Gliclazide—Malaise—Epirubicin—hematologic cancer	1.45e-05	6.57e-05	CcSEcCtD
Gliclazide—Fatigue—Prednisone—hematologic cancer	1.45e-05	6.55e-05	CcSEcCtD
Gliclazide—Headache—Prednisolone—hematologic cancer	1.45e-05	6.55e-05	CcSEcCtD
Gliclazide—Discomfort—Methotrexate—hematologic cancer	1.44e-05	6.55e-05	CcSEcCtD
Gliclazide—Nervousness—Doxorubicin—hematologic cancer	1.44e-05	6.55e-05	CcSEcCtD
Gliclazide—Leukopenia—Epirubicin—hematologic cancer	1.44e-05	6.52e-05	CcSEcCtD
Gliclazide—Back pain—Doxorubicin—hematologic cancer	1.44e-05	6.52e-05	CcSEcCtD
Gliclazide—Constipation—Prednisone—hematologic cancer	1.43e-05	6.5e-05	CcSEcCtD
Gliclazide—Palpitations—Epirubicin—hematologic cancer	1.42e-05	6.44e-05	CcSEcCtD
Gliclazide—Confusional state—Methotrexate—hematologic cancer	1.41e-05	6.41e-05	CcSEcCtD
Gliclazide—Loss of consciousness—Epirubicin—hematologic cancer	1.41e-05	6.4e-05	CcSEcCtD
Gliclazide—Dizziness—Triamcinolone—hematologic cancer	1.4e-05	6.36e-05	CcSEcCtD
Gliclazide—Cough—Epirubicin—hematologic cancer	1.4e-05	6.36e-05	CcSEcCtD
Gliclazide—Convulsion—Epirubicin—hematologic cancer	1.39e-05	6.31e-05	CcSEcCtD
Gliclazide—Infection—Methotrexate—hematologic cancer	1.39e-05	6.31e-05	CcSEcCtD
Gliclazide—Nausea—Etoposide—hematologic cancer	1.39e-05	6.3e-05	CcSEcCtD
Gliclazide—Hypertension—Epirubicin—hematologic cancer	1.39e-05	6.29e-05	CcSEcCtD
Gliclazide—Feeling abnormal—Prednisone—hematologic cancer	1.38e-05	6.26e-05	CcSEcCtD
Gliclazide—Asthenia—Betamethasone—hematologic cancer	1.38e-05	6.26e-05	CcSEcCtD
Gliclazide—Asthenia—Dexamethasone—hematologic cancer	1.38e-05	6.26e-05	CcSEcCtD
Gliclazide—Ill-defined disorder—Doxorubicin—hematologic cancer	1.38e-05	6.25e-05	CcSEcCtD
Gliclazide—Nervous system disorder—Methotrexate—hematologic cancer	1.37e-05	6.23e-05	CcSEcCtD
Gliclazide—Anaemia—Doxorubicin—hematologic cancer	1.37e-05	6.23e-05	CcSEcCtD
Gliclazide—Thrombocytopenia—Methotrexate—hematologic cancer	1.37e-05	6.22e-05	CcSEcCtD
Gliclazide—Gastrointestinal pain—Prednisone—hematologic cancer	1.37e-05	6.22e-05	CcSEcCtD
Gliclazide—Nausea—Prednisolone—hematologic cancer	1.37e-05	6.21e-05	CcSEcCtD
Gliclazide—Chest pain—Epirubicin—hematologic cancer	1.37e-05	6.2e-05	CcSEcCtD
Gliclazide—Myalgia—Epirubicin—hematologic cancer	1.37e-05	6.2e-05	CcSEcCtD
Gliclazide—Arthralgia—Epirubicin—hematologic cancer	1.37e-05	6.2e-05	CcSEcCtD
Gliclazide—Agitation—Doxorubicin—hematologic cancer	1.37e-05	6.19e-05	CcSEcCtD
Gliclazide—Anxiety—Epirubicin—hematologic cancer	1.36e-05	6.18e-05	CcSEcCtD
Gliclazide—Pruritus—Dexamethasone—hematologic cancer	1.36e-05	6.18e-05	CcSEcCtD
Gliclazide—Pruritus—Betamethasone—hematologic cancer	1.36e-05	6.18e-05	CcSEcCtD
Gliclazide—Skin disorder—Methotrexate—hematologic cancer	1.36e-05	6.17e-05	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.36e-05	6.16e-05	CcSEcCtD
Gliclazide—Hyperhidrosis—Methotrexate—hematologic cancer	1.35e-05	6.14e-05	CcSEcCtD
Gliclazide—Discomfort—Epirubicin—hematologic cancer	1.35e-05	6.13e-05	CcSEcCtD
Gliclazide—Vomiting—Triamcinolone—hematologic cancer	1.35e-05	6.12e-05	CcSEcCtD
Gliclazide—Malaise—Doxorubicin—hematologic cancer	1.34e-05	6.08e-05	CcSEcCtD
Gliclazide—Rash—Triamcinolone—hematologic cancer	1.34e-05	6.07e-05	CcSEcCtD
Gliclazide—Dry mouth—Epirubicin—hematologic cancer	1.34e-05	6.07e-05	CcSEcCtD
Gliclazide—Dermatitis—Triamcinolone—hematologic cancer	1.34e-05	6.06e-05	CcSEcCtD
Gliclazide—Urticaria—Prednisone—hematologic cancer	1.33e-05	6.04e-05	CcSEcCtD
Gliclazide—Leukopenia—Doxorubicin—hematologic cancer	1.33e-05	6.03e-05	CcSEcCtD
Gliclazide—Headache—Triamcinolone—hematologic cancer	1.33e-05	6.03e-05	CcSEcCtD
Gliclazide—Abdominal pain—Prednisone—hematologic cancer	1.33e-05	6.01e-05	CcSEcCtD
Gliclazide—Body temperature increased—Prednisone—hematologic cancer	1.33e-05	6.01e-05	CcSEcCtD
Gliclazide—Confusional state—Epirubicin—hematologic cancer	1.32e-05	6e-05	CcSEcCtD
Gliclazide—Diarrhoea—Betamethasone—hematologic cancer	1.32e-05	5.97e-05	CcSEcCtD
Gliclazide—Diarrhoea—Dexamethasone—hematologic cancer	1.32e-05	5.97e-05	CcSEcCtD
Gliclazide—Palpitations—Doxorubicin—hematologic cancer	1.31e-05	5.96e-05	CcSEcCtD
Gliclazide—Hypotension—Methotrexate—hematologic cancer	1.31e-05	5.94e-05	CcSEcCtD
Gliclazide—Loss of consciousness—Doxorubicin—hematologic cancer	1.31e-05	5.92e-05	CcSEcCtD
Gliclazide—Infection—Epirubicin—hematologic cancer	1.3e-05	5.91e-05	CcSEcCtD
Gliclazide—Cough—Doxorubicin—hematologic cancer	1.3e-05	5.88e-05	CcSEcCtD
Gliclazide—Convulsion—Doxorubicin—hematologic cancer	1.29e-05	5.84e-05	CcSEcCtD
Gliclazide—Nervous system disorder—Epirubicin—hematologic cancer	1.29e-05	5.83e-05	CcSEcCtD
Gliclazide—Thrombocytopenia—Epirubicin—hematologic cancer	1.28e-05	5.82e-05	CcSEcCtD
Gliclazide—Hypertension—Doxorubicin—hematologic cancer	1.28e-05	5.82e-05	CcSEcCtD
Gliclazide—Tachycardia—Epirubicin—hematologic cancer	1.28e-05	5.8e-05	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.28e-05	5.79e-05	CcSEcCtD
Gliclazide—Skin disorder—Epirubicin—hematologic cancer	1.27e-05	5.78e-05	CcSEcCtD
Gliclazide—Dizziness—Betamethasone—hematologic cancer	1.27e-05	5.77e-05	CcSEcCtD
Gliclazide—Dizziness—Dexamethasone—hematologic cancer	1.27e-05	5.77e-05	CcSEcCtD
Gliclazide—Hyperhidrosis—Epirubicin—hematologic cancer	1.27e-05	5.75e-05	CcSEcCtD
Gliclazide—Insomnia—Methotrexate—hematologic cancer	1.27e-05	5.75e-05	CcSEcCtD
Gliclazide—Myalgia—Doxorubicin—hematologic cancer	1.27e-05	5.74e-05	CcSEcCtD
Gliclazide—Chest pain—Doxorubicin—hematologic cancer	1.27e-05	5.74e-05	CcSEcCtD
Gliclazide—Arthralgia—Doxorubicin—hematologic cancer	1.27e-05	5.74e-05	CcSEcCtD
Gliclazide—Anxiety—Doxorubicin—hematologic cancer	1.26e-05	5.72e-05	CcSEcCtD
Gliclazide—Nausea—Triamcinolone—hematologic cancer	1.26e-05	5.71e-05	CcSEcCtD
Gliclazide—Paraesthesia—Methotrexate—hematologic cancer	1.26e-05	5.7e-05	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.26e-05	5.7e-05	CcSEcCtD
Gliclazide—Discomfort—Doxorubicin—hematologic cancer	1.25e-05	5.67e-05	CcSEcCtD
Gliclazide—Dyspnoea—Methotrexate—hematologic cancer	1.25e-05	5.66e-05	CcSEcCtD
Gliclazide—Somnolence—Methotrexate—hematologic cancer	1.25e-05	5.65e-05	CcSEcCtD
Gliclazide—Dry mouth—Doxorubicin—hematologic cancer	1.24e-05	5.61e-05	CcSEcCtD
Gliclazide—Hypersensitivity—Prednisone—hematologic cancer	1.24e-05	5.6e-05	CcSEcCtD
Gliclazide—Dyspepsia—Methotrexate—hematologic cancer	1.23e-05	5.59e-05	CcSEcCtD
Gliclazide—Hypotension—Epirubicin—hematologic cancer	1.23e-05	5.56e-05	CcSEcCtD
Gliclazide—Vomiting—Betamethasone—hematologic cancer	1.22e-05	5.55e-05	CcSEcCtD
Gliclazide—Vomiting—Dexamethasone—hematologic cancer	1.22e-05	5.55e-05	CcSEcCtD
Gliclazide—Confusional state—Doxorubicin—hematologic cancer	1.22e-05	5.55e-05	CcSEcCtD
Gliclazide—Rash—Betamethasone—hematologic cancer	1.21e-05	5.5e-05	CcSEcCtD
Gliclazide—Rash—Dexamethasone—hematologic cancer	1.21e-05	5.5e-05	CcSEcCtD
Gliclazide—Dermatitis—Dexamethasone—hematologic cancer	1.21e-05	5.5e-05	CcSEcCtD
Gliclazide—Dermatitis—Betamethasone—hematologic cancer	1.21e-05	5.5e-05	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.21e-05	5.49e-05	CcSEcCtD
Gliclazide—Fatigue—Methotrexate—hematologic cancer	1.21e-05	5.48e-05	CcSEcCtD
Gliclazide—Headache—Betamethasone—hematologic cancer	1.21e-05	5.47e-05	CcSEcCtD
Gliclazide—Headache—Dexamethasone—hematologic cancer	1.21e-05	5.47e-05	CcSEcCtD
Gliclazide—Infection—Doxorubicin—hematologic cancer	1.21e-05	5.47e-05	CcSEcCtD
Gliclazide—Asthenia—Prednisone—hematologic cancer	1.2e-05	5.45e-05	CcSEcCtD
Gliclazide—Pain—Methotrexate—hematologic cancer	1.2e-05	5.43e-05	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.19e-05	5.42e-05	CcSEcCtD
Gliclazide—Nervous system disorder—Doxorubicin—hematologic cancer	1.19e-05	5.4e-05	CcSEcCtD
Gliclazide—Thrombocytopenia—Doxorubicin—hematologic cancer	1.19e-05	5.39e-05	CcSEcCtD
Gliclazide—Pruritus—Prednisone—hematologic cancer	1.19e-05	5.38e-05	CcSEcCtD
Gliclazide—Insomnia—Epirubicin—hematologic cancer	1.19e-05	5.38e-05	CcSEcCtD
Gliclazide—Tachycardia—Doxorubicin—hematologic cancer	1.18e-05	5.37e-05	CcSEcCtD
Gliclazide—Skin disorder—Doxorubicin—hematologic cancer	1.18e-05	5.34e-05	CcSEcCtD
Gliclazide—Paraesthesia—Epirubicin—hematologic cancer	1.18e-05	5.34e-05	CcSEcCtD
Gliclazide—Hyperhidrosis—Doxorubicin—hematologic cancer	1.17e-05	5.32e-05	CcSEcCtD
Gliclazide—Dyspnoea—Epirubicin—hematologic cancer	1.17e-05	5.3e-05	CcSEcCtD
Gliclazide—Somnolence—Epirubicin—hematologic cancer	1.17e-05	5.29e-05	CcSEcCtD
Gliclazide—Feeling abnormal—Methotrexate—hematologic cancer	1.15e-05	5.24e-05	CcSEcCtD
Gliclazide—Dyspepsia—Epirubicin—hematologic cancer	1.15e-05	5.23e-05	CcSEcCtD
Gliclazide—Diarrhoea—Prednisone—hematologic cancer	1.15e-05	5.2e-05	CcSEcCtD
Gliclazide—Gastrointestinal pain—Methotrexate—hematologic cancer	1.15e-05	5.2e-05	CcSEcCtD
Gliclazide—Nausea—Dexamethasone—hematologic cancer	1.14e-05	5.19e-05	CcSEcCtD
Gliclazide—Nausea—Betamethasone—hematologic cancer	1.14e-05	5.19e-05	CcSEcCtD
Gliclazide—Hypotension—Doxorubicin—hematologic cancer	1.13e-05	5.14e-05	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.13e-05	5.13e-05	CcSEcCtD
Gliclazide—Fatigue—Epirubicin—hematologic cancer	1.13e-05	5.13e-05	CcSEcCtD
Gliclazide—Pain—Epirubicin—hematologic cancer	1.12e-05	5.08e-05	CcSEcCtD
Gliclazide—Constipation—Epirubicin—hematologic cancer	1.12e-05	5.08e-05	CcSEcCtD
Gliclazide—Urticaria—Methotrexate—hematologic cancer	1.11e-05	5.05e-05	CcSEcCtD
Gliclazide—Dizziness—Prednisone—hematologic cancer	1.11e-05	5.03e-05	CcSEcCtD
Gliclazide—Abdominal pain—Methotrexate—hematologic cancer	1.11e-05	5.02e-05	CcSEcCtD
Gliclazide—Body temperature increased—Methotrexate—hematologic cancer	1.11e-05	5.02e-05	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.11e-05	5.01e-05	CcSEcCtD
Gliclazide—Insomnia—Doxorubicin—hematologic cancer	1.1e-05	4.98e-05	CcSEcCtD
Gliclazide—Paraesthesia—Doxorubicin—hematologic cancer	1.09e-05	4.94e-05	CcSEcCtD
Gliclazide—Dyspnoea—Doxorubicin—hematologic cancer	1.08e-05	4.9e-05	CcSEcCtD
Gliclazide—Feeling abnormal—Epirubicin—hematologic cancer	1.08e-05	4.9e-05	CcSEcCtD
Gliclazide—Somnolence—Doxorubicin—hematologic cancer	1.08e-05	4.89e-05	CcSEcCtD
Gliclazide—Gastrointestinal pain—Epirubicin—hematologic cancer	1.07e-05	4.86e-05	CcSEcCtD
Gliclazide—Dyspepsia—Doxorubicin—hematologic cancer	1.07e-05	4.84e-05	CcSEcCtD
Gliclazide—Vomiting—Prednisone—hematologic cancer	1.07e-05	4.83e-05	CcSEcCtD
Gliclazide—Rash—Prednisone—hematologic cancer	1.06e-05	4.79e-05	CcSEcCtD
Gliclazide—Dermatitis—Prednisone—hematologic cancer	1.06e-05	4.79e-05	CcSEcCtD
Gliclazide—Headache—Prednisone—hematologic cancer	1.05e-05	4.76e-05	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.05e-05	4.75e-05	CcSEcCtD
Gliclazide—Fatigue—Doxorubicin—hematologic cancer	1.05e-05	4.74e-05	CcSEcCtD
Gliclazide—Urticaria—Epirubicin—hematologic cancer	1.04e-05	4.72e-05	CcSEcCtD
Gliclazide—Pain—Doxorubicin—hematologic cancer	1.04e-05	4.7e-05	CcSEcCtD
Gliclazide—Constipation—Doxorubicin—hematologic cancer	1.04e-05	4.7e-05	CcSEcCtD
Gliclazide—Abdominal pain—Epirubicin—hematologic cancer	1.04e-05	4.7e-05	CcSEcCtD
Gliclazide—Body temperature increased—Epirubicin—hematologic cancer	1.04e-05	4.7e-05	CcSEcCtD
Gliclazide—Hypersensitivity—Methotrexate—hematologic cancer	1.03e-05	4.68e-05	CcSEcCtD
Gliclazide—Asthenia—Methotrexate—hematologic cancer	1.01e-05	4.56e-05	CcSEcCtD
Gliclazide—Feeling abnormal—Doxorubicin—hematologic cancer	1e-05	4.53e-05	CcSEcCtD
Gliclazide—Nausea—Prednisone—hematologic cancer	9.96e-06	4.52e-05	CcSEcCtD
Gliclazide—Gastrointestinal pain—Doxorubicin—hematologic cancer	9.92e-06	4.5e-05	CcSEcCtD
Gliclazide—Pruritus—Methotrexate—hematologic cancer	9.91e-06	4.49e-05	CcSEcCtD
Gliclazide—Hypersensitivity—Epirubicin—hematologic cancer	9.66e-06	4.38e-05	CcSEcCtD
Gliclazide—Urticaria—Doxorubicin—hematologic cancer	9.64e-06	4.37e-05	CcSEcCtD
Gliclazide—Body temperature increased—Doxorubicin—hematologic cancer	9.59e-06	4.35e-05	CcSEcCtD
Gliclazide—Abdominal pain—Doxorubicin—hematologic cancer	9.59e-06	4.35e-05	CcSEcCtD
Gliclazide—Diarrhoea—Methotrexate—hematologic cancer	9.59e-06	4.35e-05	CcSEcCtD
Gliclazide—Asthenia—Epirubicin—hematologic cancer	9.41e-06	4.27e-05	CcSEcCtD
Gliclazide—Pruritus—Epirubicin—hematologic cancer	9.28e-06	4.21e-05	CcSEcCtD
Gliclazide—Dizziness—Methotrexate—hematologic cancer	9.27e-06	4.2e-05	CcSEcCtD
Gliclazide—Diarrhoea—Epirubicin—hematologic cancer	8.97e-06	4.07e-05	CcSEcCtD
Gliclazide—Hypersensitivity—Doxorubicin—hematologic cancer	8.94e-06	4.05e-05	CcSEcCtD
Gliclazide—Vomiting—Methotrexate—hematologic cancer	8.91e-06	4.04e-05	CcSEcCtD
Gliclazide—Rash—Methotrexate—hematologic cancer	8.83e-06	4.01e-05	CcSEcCtD
Gliclazide—Dermatitis—Methotrexate—hematologic cancer	8.83e-06	4e-05	CcSEcCtD
Gliclazide—Headache—Methotrexate—hematologic cancer	8.78e-06	3.98e-05	CcSEcCtD
Gliclazide—Asthenia—Doxorubicin—hematologic cancer	8.71e-06	3.95e-05	CcSEcCtD
Gliclazide—Dizziness—Epirubicin—hematologic cancer	8.67e-06	3.93e-05	CcSEcCtD
Gliclazide—Pruritus—Doxorubicin—hematologic cancer	8.58e-06	3.89e-05	CcSEcCtD
Gliclazide—Vomiting—Epirubicin—hematologic cancer	8.34e-06	3.78e-05	CcSEcCtD
Gliclazide—Nausea—Methotrexate—hematologic cancer	8.32e-06	3.77e-05	CcSEcCtD
Gliclazide—Diarrhoea—Doxorubicin—hematologic cancer	8.3e-06	3.76e-05	CcSEcCtD
Gliclazide—Rash—Epirubicin—hematologic cancer	8.27e-06	3.75e-05	CcSEcCtD
Gliclazide—Dermatitis—Epirubicin—hematologic cancer	8.26e-06	3.75e-05	CcSEcCtD
Gliclazide—Headache—Epirubicin—hematologic cancer	8.21e-06	3.72e-05	CcSEcCtD
Gliclazide—Dizziness—Doxorubicin—hematologic cancer	8.02e-06	3.64e-05	CcSEcCtD
Gliclazide—Nausea—Epirubicin—hematologic cancer	7.79e-06	3.53e-05	CcSEcCtD
Gliclazide—Vomiting—Doxorubicin—hematologic cancer	7.71e-06	3.5e-05	CcSEcCtD
Gliclazide—Rash—Doxorubicin—hematologic cancer	7.65e-06	3.47e-05	CcSEcCtD
Gliclazide—Dermatitis—Doxorubicin—hematologic cancer	7.64e-06	3.47e-05	CcSEcCtD
Gliclazide—Headache—Doxorubicin—hematologic cancer	7.6e-06	3.45e-05	CcSEcCtD
Gliclazide—CYP2C19—Metabolism—HMMR—hematologic cancer	7.42e-06	7.01e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—IDH2—hematologic cancer	7.42e-06	7.01e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CREBBP—hematologic cancer	7.41e-06	7e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—VEGFA—hematologic cancer	7.38e-06	6.97e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PDGFB—hematologic cancer	7.36e-06	6.96e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL2RA—hematologic cancer	7.33e-06	6.93e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—FHL2—hematologic cancer	7.28e-06	6.88e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TERT—hematologic cancer	7.25e-06	6.85e-05	CbGpPWpGaD
Gliclazide—Nausea—Doxorubicin—hematologic cancer	7.21e-06	3.27e-05	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—CREBBP—hematologic cancer	7.19e-06	6.79e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—CDK2—hematologic cancer	7.15e-06	6.75e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AGRN—hematologic cancer	7.14e-06	6.74e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—IDH1—hematologic cancer	7.11e-06	6.72e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PDGFB—hematologic cancer	7.07e-06	6.68e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ABCC3—hematologic cancer	7.03e-06	6.64e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TXN—hematologic cancer	7.03e-06	6.64e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTO1—hematologic cancer	7.03e-06	6.64e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CD—hematologic cancer	7.03e-06	6.64e-05	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—AKT1—hematologic cancer	7.01e-06	6.62e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	7e-06	6.61e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—MAPK3—hematologic cancer	6.98e-06	6.59e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ARNTL—hematologic cancer	6.98e-06	6.59e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ALB—hematologic cancer	6.94e-06	6.56e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TSC2—hematologic cancer	6.91e-06	6.53e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SPHK1—hematologic cancer	6.88e-06	6.5e-05	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—AKT1—hematologic cancer	6.87e-06	6.5e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MAPK14—hematologic cancer	6.86e-06	6.48e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CD—hematologic cancer	6.81e-06	6.44e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CA9—hematologic cancer	6.79e-06	6.41e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ACP5—hematologic cancer	6.79e-06	6.41e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—TGFB1—hematologic cancer	6.77e-06	6.4e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—HMMR—hematologic cancer	6.77e-06	6.39e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—IDH2—hematologic cancer	6.77e-06	6.39e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ALB—hematologic cancer	6.73e-06	6.36e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NCOR2—hematologic cancer	6.7e-06	6.33e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FGFR3—hematologic cancer	6.65e-06	6.29e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—FN1—hematologic cancer	6.64e-06	6.28e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3R1—hematologic cancer	6.64e-06	6.27e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—UGT1A1—hematologic cancer	6.61e-06	6.24e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAPK14—hematologic cancer	6.59e-06	6.22e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ESR1—hematologic cancer	6.46e-06	6.1e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3R1—hematologic cancer	6.43e-06	6.08e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SLC22A1—hematologic cancer	6.43e-06	6.07e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CRABP1—hematologic cancer	6.43e-06	6.07e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FN1—hematologic cancer	6.38e-06	6.03e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—IDH1—hematologic cancer	6.38e-06	6.03e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	6.38e-06	6.03e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ARNTL—hematologic cancer	6.36e-06	6.01e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CG—hematologic cancer	6.36e-06	6.01e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TXN—hematologic cancer	6.31e-06	5.96e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ABCC3—hematologic cancer	6.31e-06	5.96e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTO1—hematologic cancer	6.31e-06	5.96e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NFKBIA—hematologic cancer	6.31e-06	5.96e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—BAD—hematologic cancer	6.31e-06	5.96e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ALOX5—hematologic cancer	6.26e-06	5.92e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PTPN11—hematologic cancer	6.25e-06	5.9e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NOTCH1—hematologic cancer	6.24e-06	5.9e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ACP5—hematologic cancer	6.19e-06	5.85e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CA9—hematologic cancer	6.19e-06	5.85e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SPHK1—hematologic cancer	6.17e-06	5.83e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CB—hematologic cancer	6.13e-06	5.79e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CD80—hematologic cancer	6.12e-06	5.78e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NCOR2—hematologic cancer	6.11e-06	5.77e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KIT—hematologic cancer	6.11e-06	5.77e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CG—hematologic cancer	6.11e-06	5.77e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NUP98—hematologic cancer	6.07e-06	5.73e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTPN11—hematologic cancer	6e-06	5.67e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CB—hematologic cancer	5.94e-06	5.61e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—UGT1A1—hematologic cancer	5.93e-06	5.61e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—CREBBP—hematologic cancer	5.89e-06	5.57e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ADCY7—hematologic cancer	5.89e-06	5.57e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NCOA3—hematologic cancer	5.89e-06	5.57e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NUP214—hematologic cancer	5.85e-06	5.53e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—IDH1—hematologic cancer	5.82e-06	5.5e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CREB1—hematologic cancer	5.81e-06	5.49e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	5.79e-06	5.47e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SLC22A1—hematologic cancer	5.77e-06	5.45e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CRABP1—hematologic cancer	5.77e-06	5.45e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CA—hematologic cancer	5.76e-06	5.44e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TXN—hematologic cancer	5.75e-06	5.44e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTO1—hematologic cancer	5.75e-06	5.44e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ABCC3—hematologic cancer	5.75e-06	5.44e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—BRAF—hematologic cancer	5.74e-06	5.42e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—MTR—hematologic cancer	5.73e-06	5.41e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ABCG2—hematologic cancer	5.73e-06	5.41e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCL2—hematologic cancer	5.69e-06	5.37e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6R—hematologic cancer	5.67e-06	5.36e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CREBBP—hematologic cancer	5.66e-06	5.35e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SPHK1—hematologic cancer	5.63e-06	5.32e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALOX5—hematologic cancer	5.62e-06	5.31e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ENO2—hematologic cancer	5.62e-06	5.31e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CD—hematologic cancer	5.59e-06	5.28e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTT1—hematologic cancer	5.45e-06	5.15e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NUP98—hematologic cancer	5.45e-06	5.15e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—UGT1A1—hematologic cancer	5.41e-06	5.11e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAP2K1—hematologic cancer	5.4e-06	5.11e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CD—hematologic cancer	5.37e-06	5.07e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	5.37e-06	5.07e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SDC1—hematologic cancer	5.33e-06	5.03e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTEN—hematologic cancer	5.29e-06	5e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ADCY7—hematologic cancer	5.29e-06	5e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NCOA3—hematologic cancer	5.29e-06	5e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3R1—hematologic cancer	5.28e-06	4.99e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SLC22A1—hematologic cancer	5.26e-06	4.97e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CRABP1—hematologic cancer	5.26e-06	4.97e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NUP214—hematologic cancer	5.25e-06	4.96e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	5.2e-06	4.91e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—MTR—hematologic cancer	5.14e-06	4.86e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ABCG2—hematologic cancer	5.14e-06	4.86e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FGF2—hematologic cancer	5.14e-06	4.86e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTEN—hematologic cancer	5.13e-06	4.85e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—JAK2—hematologic cancer	5.13e-06	4.85e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALOX5—hematologic cancer	5.13e-06	4.84e-05	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—CREBBP—hematologic cancer	5.1e-06	4.82e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	5.09e-06	4.81e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3R1—hematologic cancer	5.07e-06	4.79e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—EP300—hematologic cancer	5.05e-06	4.77e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ENO2—hematologic cancer	5.04e-06	4.77e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NUP98—hematologic cancer	4.97e-06	4.69e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—JAK2—hematologic cancer	4.93e-06	4.66e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—EP300—hematologic cancer	4.89e-06	4.63e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTT1—hematologic cancer	4.89e-06	4.62e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CB—hematologic cancer	4.87e-06	4.6e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ADCY7—hematologic cancer	4.82e-06	4.56e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NCOA3—hematologic cancer	4.82e-06	4.56e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	4.82e-06	4.55e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MDM2—hematologic cancer	4.81e-06	4.54e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	4.8e-06	4.54e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NUP214—hematologic cancer	4.79e-06	4.52e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SDC1—hematologic cancer	4.78e-06	4.52e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	4.74e-06	4.48e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—AKT1—hematologic cancer	4.71e-06	4.45e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—MTR—hematologic cancer	4.69e-06	4.43e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ABCG2—hematologic cancer	4.69e-06	4.43e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CB—hematologic cancer	4.68e-06	4.42e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MTOR—hematologic cancer	4.68e-06	4.42e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ENO2—hematologic cancer	4.6e-06	4.35e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	4.57e-06	4.32e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CD44—hematologic cancer	4.53e-06	4.28e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NQO1—hematologic cancer	4.53e-06	4.28e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	4.51e-06	4.26e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IL2—hematologic cancer	4.47e-06	4.23e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTT1—hematologic cancer	4.46e-06	4.21e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	4.43e-06	4.19e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	4.39e-06	4.15e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN1B—hematologic cancer	4.39e-06	4.15e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SDC1—hematologic cancer	4.36e-06	4.12e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	4.31e-06	4.08e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CASP3—hematologic cancer	4.3e-06	4.07e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL2—hematologic cancer	4.3e-06	4.06e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYCS—hematologic cancer	4.29e-06	4.05e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—HSP90AA1—hematologic cancer	4.26e-06	4.02e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCND1—hematologic cancer	4.19e-06	3.96e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—JUN—hematologic cancer	4.18e-06	3.95e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	4.16e-06	3.94e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	4.11e-06	3.88e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NQO1—hematologic cancer	4.07e-06	3.84e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CD44—hematologic cancer	4.07e-06	3.84e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN1A—hematologic cancer	4.05e-06	3.83e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTEN—hematologic cancer	4.04e-06	3.82e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—EP300—hematologic cancer	4.01e-06	3.79e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	3.98e-06	3.76e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAPK8—hematologic cancer	3.96e-06	3.74e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	3.93e-06	3.72e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SRC—hematologic cancer	3.9e-06	3.69e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EP300—hematologic cancer	3.86e-06	3.64e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYCS—hematologic cancer	3.85e-06	3.64e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.83e-06	3.62e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	3.82e-06	3.61e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—VEGFA—hematologic cancer	3.8e-06	3.59e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTP1—hematologic cancer	3.78e-06	3.57e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NRAS—hematologic cancer	3.76e-06	3.55e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SRC—hematologic cancer	3.75e-06	3.54e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CA—hematologic cancer	3.73e-06	3.53e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NQO1—hematologic cancer	3.71e-06	3.5e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CD44—hematologic cancer	3.71e-06	3.5e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.65e-06	3.45e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	3.63e-06	3.43e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CA—hematologic cancer	3.62e-06	3.42e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—STAT3—hematologic cancer	3.62e-06	3.42e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NRAS—hematologic cancer	3.61e-06	3.41e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MAPK3—hematologic cancer	3.6e-06	3.4e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ABCB1—hematologic cancer	3.58e-06	3.38e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYCS—hematologic cancer	3.51e-06	3.31e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TGFB1—hematologic cancer	3.49e-06	3.3e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	3.49e-06	3.29e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTM1—hematologic cancer	3.47e-06	3.28e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NCOR1—hematologic cancer	3.47e-06	3.28e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAPK3—hematologic cancer	3.45e-06	3.26e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.44e-06	3.25e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTP1—hematologic cancer	3.39e-06	3.2e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MYC—hematologic cancer	3.36e-06	3.18e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TGFB1—hematologic cancer	3.35e-06	3.17e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.28e-06	3.1e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—KRAS—hematologic cancer	3.23e-06	3.05e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ABCB1—hematologic cancer	3.21e-06	3.03e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.14e-06	2.96e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NCOR1—hematologic cancer	3.12e-06	2.94e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTM1—hematologic cancer	3.12e-06	2.94e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KRAS—hematologic cancer	3.1e-06	2.93e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTP1—hematologic cancer	3.09e-06	2.92e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—MTHFR—hematologic cancer	3.07e-06	2.9e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—AKT1—hematologic cancer	3.05e-06	2.88e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.99e-06	2.83e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CA—hematologic cancer	2.97e-06	2.81e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—AKT1—hematologic cancer	2.96e-06	2.79e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ABCB1—hematologic cancer	2.93e-06	2.77e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—hematologic cancer	2.87e-06	2.71e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CA—hematologic cancer	2.85e-06	2.7e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NCOR1—hematologic cancer	2.84e-06	2.68e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTM1—hematologic cancer	2.84e-06	2.68e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—hematologic cancer	2.76e-06	2.61e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—MTHFR—hematologic cancer	2.75e-06	2.6e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—HRAS—hematologic cancer	2.75e-06	2.6e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.7e-06	2.55e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HRAS—hematologic cancer	2.64e-06	2.49e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CG—hematologic cancer	2.58e-06	2.44e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6—hematologic cancer	2.53e-06	2.39e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—MTHFR—hematologic cancer	2.51e-06	2.37e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.43e-06	2.29e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—AKT1—hematologic cancer	2.43e-06	2.29e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CREBBP—hematologic cancer	2.39e-06	2.26e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKT1—hematologic cancer	2.33e-06	2.2e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CG—hematologic cancer	2.31e-06	2.19e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CD—hematologic cancer	2.27e-06	2.14e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.21e-06	2.09e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CREBBP—hematologic cancer	2.15e-06	2.03e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3R1—hematologic cancer	2.14e-06	2.02e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CG—hematologic cancer	2.11e-06	1.99e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CD—hematologic cancer	2.03e-06	1.92e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALB—hematologic cancer	2.01e-06	1.9e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CB—hematologic cancer	1.97e-06	1.87e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CREBBP—hematologic cancer	1.96e-06	1.85e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3R1—hematologic cancer	1.92e-06	1.81e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CD—hematologic cancer	1.85e-06	1.75e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALB—hematologic cancer	1.83e-06	1.73e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CB—hematologic cancer	1.77e-06	1.68e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3R1—hematologic cancer	1.75e-06	1.65e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTEN—hematologic cancer	1.71e-06	1.61e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—EP300—hematologic cancer	1.63e-06	1.54e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CB—hematologic cancer	1.62e-06	1.53e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTEN—hematologic cancer	1.53e-06	1.45e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—EP300—hematologic cancer	1.46e-06	1.38e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTEN—hematologic cancer	1.4e-06	1.32e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—EP300—hematologic cancer	1.33e-06	1.26e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CA—hematologic cancer	1.2e-06	1.14e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CA—hematologic cancer	1.08e-06	1.02e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CA—hematologic cancer	9.85e-07	9.31e-06	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AKT1—hematologic cancer	9.84e-07	9.29e-06	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKT1—hematologic cancer	8.83e-07	8.34e-06	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKT1—hematologic cancer	8.05e-07	7.61e-06	CbGpPWpGaD
